Supernus Pharmaceuticals (SUPN)
Add to Watchlists Create an Alert
6.82
+0.17 +2.56%
NASDAQ
May 24, 5:00PM
BATS Real time
Currency in USD
Supernus Pharmaceuticals Return on Equity:
-178.2% for Dec. 31, 2012Supernus Pharmaceuticals Historical Return on Equity Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | -178.2% |
About Return on Equity (ROE)
Return on equity (ROE) measures the rate of return on the money invested by common stock owners and retained by the company thanks to previous profitable years. It demonstrates a company's ability to generate profits from shareholders' equity (also known as net assets or assets minus liabilities).
ROE shows how well a company uses investment funds to generate growth. Return on equity is useful for comparing the profitability of companies within a sector or industry.
Investors generally are interested in company's that have high, increasing returns on equity.
Learn More
SUPN Return on Equity Benchmarks
| Companies | |
|---|---|
| Pernix Therapeutics | -2.08% |
| Catalyst Pharmaceutical Partners | -55.23% |
| Lannett Company | 7.98% |
SUPN Return on Equity Rankings
| Overall |
43rd percentile 4508 of 8009 |
| Sector |
31st percentile 474 of 687 in Healthcare |
| Industry |
28th percentile 49 of 69 in Drug Manufacturers - Specialty & Generic |
SUPN Return on Equity Range, Past 5 Years
| Minimum | -178.2% | Dec 2012 |
| Maximum | -178.2% | Dec 2012 |
| Average | -178.2% |
SUPN News
Supernus (SUPN) PT Trimmed at Jefferies, But Survey Shows Significant Market Opportunity
Street Insider May 17
Street Insider May 17
